Clinical Trials Browser

tislelizumab × Head & Neck × Clear all

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms

NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT05909904 2025-10-07

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03744468 2025-10-02

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Completed

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Phase 2 Recruiting

Head and Neck Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT07010120 2025-06-13

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06009861 2025-06-06

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT06673693 2025-04-16

NEOSTART

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06258811 2025-03-13

Neoadjuvant Immunochemotherapy for LAOSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

NCT06781112 2025-01-17

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06741982 2024-12-19

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06728618 2024-12-11

OSCC

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06554028 2024-08-14

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase 2 Not yet recruiting

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT06383780 2024-07-16

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05211232 2024-04-18

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT06366945 2024-04-16

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT05862168 2023-07-17

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05343325 2022-12-29

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Phase 2 Unknown

Thyroid Neoplasms

NCT05595590 2022-10-27

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Phase 2 Recruiting

Head and Neck Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT04921995 2022-04-04

RETICULA-NPC

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04814069 2021-03-24

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

Phase 2 Unknown

Head and Neck Neoplasms